BEIJING, June 24 /PRNewswire-Asia/ -- Cellonis, a Beijing and HK-based biotech company, with its new personalized diabetes treatment concept has demonstrated an amazing improvement in their treated patients' conditions. The ongoing clinical study shows the treatment's best case could reconstruct a patient's natural insulin production and even reverse later complications like kidney failure. Treated patients may have the chance to return to the normal activities non-diabetes sufferers take for granted.

Jerusalem, Israel, June 21, 2010 --- Gamida Cell announced today that the Gamida Cell-Teva Joint Venture has received an FDA Fast Track Designation for StemEx, in development as an alternative to a bone marrow transplant for patients with blood cancers such as leukemia and lymphoma.

The fast track programs of the Food and Drug Administration (FDA) are designed to facilitate the development and expedite the review of new drugs that are intended to treat serious or life threatening conditions and that demonstrate the potential to address unmet medical needs (fast track products).

BEIJING, 18 JUNE 2010. Scientists in China have successfully engineered myocardial tissue (heart muscle) that is likely to share structural and functional similarities with natural myocardium according to new data presented today at the World Congress of Cardiology (WCC) Scientific Sessions in Beijing, China.

Heart disease can lead to damage or death of heart muscle, which can cause a heart attack and/or eventually lead to heart failure. Pharmacologic and interventional treatment can decelerate but not stop the progression of heart failure and for many patients a heart transplant is their only hope. However, the lack of available donor organs significantly limits the number of heart transplantations that are carried out. Myocardial tissue engineering offers one promising strategy for the future.

SAN FRANCISCO Stem cell scientists from around the world gathered at the International Society of Stem Cell Research (ISSCR) in San Francisco to exchange information about the latest treatments with stem cells. An American company, TCA Cellular Therapy, LLC announced its FDA clinical trial results using adult stem cells in patients with history of a heart attack during open heart surgery.

"I anticipate that in the near future adult stem cells will be offered to patients with a history of heart attack who are going to have bypass surgery"

Soldiers in combat suffer massive wounds to bone and tissue quite unlike most injuries that civilian doctors treat. Explosive blasts, rarely encountered in civilian life, cause about 2/3 of the injuries in Iraq. Musculoskeletal injuries account for about 70% of war wounds, and 55% of those are wounds to the arms and legs. Fractures account for 26% of combat injuries.

Thanks to advances in medical care and body and vehicle armor, 90% of these wounded soldiers survive. Their severe injuries, however, may require numerous surgeries for reconstruction. Strategies to improve and speed bone healing could reduce the number of orthopaedic surgeries required and improve patient outcomes for a large percentage of all wounded soldiers.